Promising drug targets teen brain tumors in new trial
NCT ID NCT07286292
First seen Jan 11, 2026 · Last updated May 06, 2026 · Updated 18 times
Summary
This study is testing a drug called vorasidenib in teenagers aged 12 to 17 who have a slow-growing type of brain tumor (grade 2 astrocytoma or oligodendroglioma) with a specific gene mutation (IDH1 or IDH2). The goal is to see if the drug is safe, how well it works, and how it affects growth and development. Participants will take the drug in 28-day cycles and be monitored for about 5 years.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for GRADE 2 ASTROCYTOMA OR OLIGODENDROGLIOMA WITH AN IDH1 OR IDH2 MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.